CYLD and hepatocellular carcinoma: Since the present retrospective study identifies a subgroup of patients with improved OS after curative resection and liver transplantation (nucCYLD+), nuclear CYLD expression might be an interesting biomarker for prospective clinical trials in the adjuvant setting after HCC surgery.